LP-003 is under clinical development by Tianchen Biopharmaceutical (Suzhou) and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LP-003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LP-003 overview
LP-003 is under development for the treatment of asthma, chronic spontaneous urticaria and seasonal allergic rhinitis. It is administered through subcutaneous and intravenous route.
Tianchen Biopharmaceutical (Suzhou) overview
Tianchen Biopharmaceutical (Suzhou) (Tianchen Biomedicine) is an innovative drug research and development company focused on developing biological macromolecules. Tianchen Biomedicine is headquartered in Shanghai, China.
For a complete picture of LP-003’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.